Healthcare · Biotechnology
Price
$2.43
Market Cap
$210.4M
Employees
140
Beta
1.57
Avg Volume
1,292,416
CEO
Brent Pfeiffenberger
Business Description
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Business History
Price Overview
Price at report time · Jul 3, 4:54am (0m ago)
$2.43
Change · Jul 3
+0.04 (+1.67%)
Day Range
$2.36 – $2.50
52-Week Range
$0.44 – $3.04
50-Day MA
$2.28
200-Day MA
$1.60
Volume
838,963.00
Right now · live
loading…
Real-time — the change above is the move since the report (over 0m).
Analyst Price Targets
Low
$2.00
Consensus
$3.00
High
$4.00
(8 analysts)
Share Structure
Outstanding
86,569,389.00
Float
48,646,042.00
Free Float
56.2%
Normal free float
— 56.2% of shares trade freely, ~43.8% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-22.09
Stock Price: $2.43
EPS (Diluted): -0.11
EPS (Diluted): -0.11
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.54
Stock Price: $2.43
Total Equity: $158.94M
Shares: 86,556,515
Total Equity: $158.94M
Shares: 86,556,515
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-2.31
Market Cap: $210.36M
Total Debt: $0.00
Cash: $61.85M
EBITDA: $3.45M
Total Debt: $0.00
Cash: $61.85M
EBITDA: $3.45M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$67.8M
Market Cap: $210.36M
Total Debt: $0.00
Cash: $61.85M
Total Debt: $0.00
Cash: $61.85M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.79
Stock Price: $2.43
Revenue: $109.16M
Shares: 86,556,515
Revenue: $109.16M
Shares: 86,556,515
EV/Sales (Total value vs revenue — works when P/E can't)
API0.62
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
88.0%
Gross Profit: $96.06M
Revenue: $109.16M
Revenue: $109.16M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-13.8%
Operating Income: -$15.04M
Revenue: $109.16M
Revenue: $109.16M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-8.8%
Net Income: -$9.58M
Revenue: $109.16M
Revenue: $109.16M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-53.2%
Net Income: -$9.58M
Total Equity: $158.94M
Total Equity: $158.94M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-36.9%
Operating Income: -$15.04M
Tax Rate: 0.7%
Equity: $158.94M
Total Debt: $0.00
Cash: $61.85M
Tax Rate: 0.7%
Equity: $158.94M
Total Debt: $0.00
Cash: $61.85M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
5.97
Current Assets: $120.77M
Current Liabilities: $20.23M
Current Liabilities: $20.23M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $158.94M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $158.94M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$1.26
Revenue: $109.16M
Shares: 86,556,515
Shares: 86,556,515
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.84
Total Equity: $158.94M
Shares: 86,556,515
Shares: 86,556,515
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.21
Operating CF: -$103.88M
CapEx: -$848,000
Shares: 86,556,515
CapEx: -$848,000
Shares: 86,556,515
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.43
Stock Price: $2.43
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$9.58M
Net Income: -$9.58M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares IPSC against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 3, 2026 4:54am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $5.2M | $2.2M | $6.6M | $109.2M |
| Cost of Revenue | $4.6M | $0 | $0 | $0 | $13.1M |
| Gross Profit | -$4.6M | $5.2M | $2.2M | $6.6M | $96.1M |
| Operating Expenses | $90.3M | $139.0M | $148.8M | $144.7M | $111.1M |
| Operating Income | -$94.9M | -$133.8M | -$146.5M | -$138.1M | -$15.0M |
| Net Income | -$95.8M | -$130.9M | -$136.7M | -$126.6M | -$9.6M |
| EBITDA | -$89.9M | -$121.2M | -$121.2M | -$111.5M | $3.5M |
| EPS | $-1.74 | $-2.27 | $-2.30 | $-1.61 | $-0.11 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 3, 2026 4:54am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $56.4M | $84.3M | $47.3M | $58.4M | $61.9M |
| Total Current Assets | $228.2M | $319.7M | $177.0M | $194.1M | $120.8M |
| Total Assets | $437.4M | $486.5M | $360.7M | $353.2M | $223.7M |
| Current Liabilities | $15.7M | $29.8M | $17.8M | $129.8M | $20.2M |
| Long-Term Debt | $8.9M | $3.7M | $0 | $0 | $0 |
| Total Liabilities | $41.1M | $183.8M | $175.9M | $191.9M | $64.8M |
| Total Equity | $396.2M | $302.7M | $184.8M | $161.4M | $158.9M |
| Retained Earnings | -$388.2M | -$519.1M | -$655.8M | -$782.3M | -$791.9M |
Cash Flow (Annual)
Last updated: Jul 3, 2026 4:54am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$89.0M | $14.1M | -$88.3M | -$110.1M | -$103.9M |
| Capital Expenditure | -$45.0M | -$30.6M | -$13.7M | $-154,000 | $-848,000 |
| Free Cash Flow | -$134.0M | -$16.6M | -$102.1M | -$110.3M | -$104.7M |
| Acquisitions (net) | $0 | -$238.2M | $0 | -$9.6M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $30.4M | $28.1M | -$36.9M | $11.9M | $3.8M |
Analyst Estimates (Annual)
Last updated: Jul 3, 2026 4:54am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$3.7M $3.7M – $3.7M
|
$1.2M $1.2M – $1.2M
|
$375,000 $375,000 – $375,000
|
$77.6M $77.6M – $77.6M
|
| EBITDA |
-$1.5M -$1.5M – -$1.5M
|
$-464,535 $-464,535 – $-464,535
|
$-147,627 $-147,627 – $-147,627
|
-$30.5M -$30.5M – -$30.5M
|
| Net Income |
-$36.4M -$48.5M – -$24.2M
|
-$30.0M -$33.4M – -$26.7M
|
-$31.4M -$31.4M – -$31.4M
|
-$38.5M -$38.5M – -$38.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 3, 2026 4:54am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | -57.0% | +194.8% | +1,556.8% |
| Gross Profit Growth | +213.5% | -57.0% | +194.8% | +1,357.9% |
| Operating Income Growth | -41.0% | -9.5% | +5.7% | +89.1% |
| Net Income Growth | -36.6% | -4.4% | +7.4% | +92.4% |
| EBITDA Growth | -34.8% | 0.0% | +8.0% | +103.1% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Russotti Gregory | S-Sale | 2,584.00 | $2.23 | $5,767 |
| 2026-06-12 | Carr Douglas | S-Sale | 1,654.00 | $2.23 | $3,692 |
| 2026-06-11 | Pfeiffenberger Brent | F-InKind | 13,849.00 | $2.24 | $31,022 |
| 2026-06-11 | Cowan Chad | F-InKind | 358.00 | $2.24 | $802 |
| 2026-06-11 | Riva Alessandro | A-Award | 74,000.00 | $2.24 | $165,760 |
| 2026-06-11 | Quimi Daphne | A-Award | 74,000.00 | $2.24 | $165,760 |
| 2026-06-11 | Murphy Martin Patrick | A-Award | 74,000.00 | $2.24 | $165,760 |
| 2026-06-11 | Lee Han Myung | A-Award | 74,000.00 | $2.24 | $165,760 |
| 2026-06-11 | Blackwell Kimberly | A-Award | 74,000.00 | $2.24 | $165,760 |
| 2026-06-08 | Russotti Gregory | S-Sale | 524.00 | $2.11 | $1,106 |
| 2026-06-08 | Carr Douglas | S-Sale | 249.00 | $2.11 | $526 |
| 2026-06-05 | Pfeiffenberger Brent | F-InKind | 463.00 | $2.13 | $986 |
| 2026-05-15 | Pfeiffenberger Brent | F-InKind | 31,172.00 | $2.34 | $72,942 |
| 2026-05-04 | Carr Douglas | S-Sale | 264.00 | $2.34 | $618 |
| 2025-12-09 | Murphy Martin Patrick | A-Award | 88,000.00 | $0.59 | $52,096 |
| 2025-12-09 | Murphy Martin Patrick | 0.00 | $0.00 | $0 | |
| 2026-04-01 | Cowan Chad | F-InKind | 1,365.00 | $2.19 | $2,989 |
| 2026-03-12 | Carr Douglas | S-Sale | 7,043.00 | $2.55 | $17,953 |
| 2026-03-12 | Russotti Gregory | S-Sale | 10,076.00 | $2.55 | $25,684 |
| 2026-03-11 | Pfeiffenberger Brent | F-InKind | 55,397.00 | $2.73 | $151,234 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for IPSC — it's generated by the pipeline (
market-narrative step).
No community reviews yet for IPSC.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.373 · 697c9e64 · 2026-07-02 20:17:59